JPMorgan analyst Richard Vosser raised the firm’s price target on GSK to 1,400 GBp from 1,350 GBp and keeps an Underweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- Akebia should update on vadadustat FDA process in next month, says Piper Sandler
- GSK reports Jesduvroq approved by FDA for anemia of CKD in adults on dialysis
- Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
- GSK sees FY23 adjusted EPS up 12%-15%, adjusted operating profit up 10%-12%
- GSK reports Benlysta granted orphan drug designation by FDA